Both hospital and outpatient products, as well as orphan drugs have been included in this analysis. All medicinal products have been assessed on the INN level, without differentiating original, innovative products from generics. In addition to general statistical analysis, the GDP adjusted comparison has also been performed. Subsequently we have also conducted more detailed analysis of the following ATC groups, known to be major health care cost drivers: C (cardiovascular), J (anti-infective), L (oncology), M (musculo-skeletal) and N (neurology, psychiatry). RESULTS: As expected, linear correlation between national GDP and number of reimbursed INNs have been observed. However, major differences in mentioned ATC groups have revealed the inconsistency of the current HTA activities across countries leading to sometimes unfair treatment possibilities for patients with different diseases which could have not been justified by unequal socio-economic characteristics of investigated countries. CONCLUSIONS: There is a strong need for the continuous education of national decision makers on the principles and processes of the HTA. New innovative ideas of financing the health care in developing countries are urgently needed in order to ensure ethical standards in health care and subsequent patient access to cost effective treatment, but at the same time to engage patients in investing in their personal health and wellbeing.
HEALTH CARE USE & POLICY STUDIES -Formulary Development

PHP36 HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS
Mullins CD 1 , Ratner J 2 , Ball D 3 1 University of Maryland, Baltimore, MD, USA, 2 Westat, Rockville, MD, USA, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Since the 1990s, many articles have documented problems with US payers' utilization of pharmacoeconomic studies for decision-making. By replicating an in-depth survey methodology, this study aimed to determine the extent to which US practices had changed over the past decade. METHODS: Semi-structured exploratory interviews were conducted in 2007 to develop a survey instrument-fielded in 2007-08 with key formulary decision-makers at US insurers and US public payers in 9 pre-identified categories. The structured set of questions examined US health care payers' 1) use of, and attitudes and perceptions regarding, pharmacoeconomic information, and 2) opinions about how pharmaceutical manufacturers present pharmacoeconomic information. RESULTS: Compared to 10 years ago, U.S. payers regard pharmacoeconomic information much more favorably, despite variation in their use of and attitudes toward pharmacoeconomics. Payers cluster in three groups: a minority who use pharmacoeconomic information frequently and rigorously; a broader group who examine pharmacoeconomic information informally and do rigorous analysis occasionally; and a group who only review pharmacoeconomic information in broad terms along with other drug-related information. Across all categories, payers acknowledge that the quality of pharmacoeconomic studies has improved. Payers suggest that pharmacoeconomic studies often "answer the wrong questions"-e.g., by failing to identify the subset(s) of patients where the drug is most effective. Payers remain skeptical towards pharmacoeconomic information and studies provided/sponsored by industry-e.g., when they perceive companies present only favorable studies. Increasingly, payers separate clinical reviews from pharmacoeconomic evaluations; the latter may be integrated with rebating discussions. CONCLUSIONS: US payer attitudes about and use of pharmacoeconomic information have improved; however, formal, rigorous use of cost-effectiveness analysis is not the norm. Most payers foresee their organizations using pharmacoeconomic evaluation slightly more and would welcome a neutral entity that produced pharmacoeconomic evidence-although some question whether even government funding could insulate it from industry and political influence.
HEALTH CARE USE & POLICY STUDIES -Health Care Costs & Management
PHP37 SOCIAL HEALTH INSURANCE, PREVENTIVE CARE AND HEALTH CARE EXPENDITURE
Chen Q 1 , Li J 2 , Li L 1 1 Peking University, Beijing, China, 2 Peking University, Beijing, Beijing, China OBJECTIVES: Social Health Insurance (SHI) and National Health Service (NHS) are two main choices for health reform. China's health reform during last decade is basically SHI-oriented, especially after the implementation of "Basic health Insurance of Urban Workers" since 1998. Theoretically speaking, a NHS system will invest more on preventive care than an SHI system. This research investigates the effect of increasing health insurance coverage on health expenditure in China, especially through the specific channel of preventive care. METHODS: We estimates the health care expenditure function with province-level panel data from 1991-2007 of China.
The key determinates we examined are social health insurance policy implication (the increaseing coverage of health insurance) and the share of preventive care in health disbursement. Other determinants are those usually in literatures including GDP, doctor and beds supply, population, aging. The independent variables of interests are per capita health expenditure, hospitalization expenses, inspecting commission and medical expenses. A generalized difference-in-difference method is used to assess the effect of adoption of social health insurance. IV methods are used to control the possible endogeneity problems. RESULTS: The increasing coverage of health insurance is expected to contribute to health care expenditure increasing. The more is the spending of preventive health care, the lower the health expenditure is. Moreover, we find social health insurance coverage has a crowding-out effect on preventive care expenditure. Other variables' effects are similar to the results from literatures. CONCLUSIONS: "Low accessibility and high costs in health care service" is key problem of China's health care system right now. The SHI oriented health reform is a driver of health care expenditure increasing. China has just stated of a new comprehensive heath care system reform. The move to SHI may be politically correct, but is not the best option for China. It will lead to long-term and deep crisis in the health sector.
PHP38 HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY
University of Thessaly, Athens, Greece, 2 University of Thessaly, Volos, Greece OBJECTIVES: To estimate the hospitalisation cost of ICU patients admitted to the TUHL in the region of Thessaly, in Greece.
in the region of Thessaly, in Greece. region of Thessaly, in Greece. of Thessaly, in Greece. METHODS: The ICU chosen is the only tertiary university ICU in the whole region of Thessaly accounting 27% of the total ICU beds. The study sample consisted of all patients (elective and emergency admissions) admitted to the respective TUHL in 2006. Clinical data were derived from were derived from patients' medical records on a retrospective basis whereas economic data were derived from the Hospital's Financial Department. The analysis included direct costs, using an up-down approach under NHS perspective. The nominal and actual hospitalization cost per ICU patient were based on the resource utilisation and the annual hospital balance sheets on NHS prices in Euros. RESULTS: 312 have been admitted to the ICU with a total direct cost of a4,799 million suffering from stroke, COPD, cancer, cancer, heart, trauma, pneumonia with a mean length of stay 8.87 days. The mean cost per hospitalisation day in the ICU was estimated at a1,734. Mean actual cost per patient is estimated at a15,382 whereas social insurance funds reimburse only a1,666. Personnel costs are the major cost component accounting for 31% of the total cost, while the pharmaceuticals account for 23%, laboratory 11%, supply and oxygen 17%, infrastructure-hotel services expenses 18%. CONCLUSIONS: This research results in some meaningful conclusions for effecting changes in hospital policies for better utilization of ICU resources, for optimizing patient care and incorporating economic incorporating economic assessment in decision-making. The objective of the study is to obtain behaviour of the cost's relative average weights of the assistance with the retrospective application of the Adjusted Clinical Groups (ACG's) in 16 teams of Primary Care with an attended population in the clinical practice use.
PHP39 COST MEASURE IN PRIMARY CARE: RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL
ical practice use. METHODS: Multicentre, retrospective study based on electronic records of patients seeking care during 2008 in the regions of Aragon, Balears and Catalonia. Main measurements: universal variables (age, sex, health service-family practice/paediatrics) and dependent variables: episodes and total paediatrics) and dependent variables: episodes and total cost (visits, diagnostic test, referrals, drugs). The ACG case-mix System software (version 7.1; N 106) classified subjects into a single category for a given annual 106) classified subjects into a single category for a given annual resource consumption. The model of cost per each patient was established differencing odel of cost per each patient was established differencing the fix cost and the variable. Outlier patients were considered those surpassing T Q3 Q3 1.5(Q3-Q1) a1,778.6 for total cost expenditure. Log transformation of the dependent variable was carried out to reduce skewness of the distribution and e was carried out to reduce skewness of the distribution and make it close to normal. Explanatory power was calculated by coefficients of determination (R2). Statistical software: SPSS, p 0.05. 0.05. RESULTS: The total number of the studied patients was 227,235 (intensity of use: 75.6%), with an average 4.5 7,235 (intensity of use: 75.6%), with an average 4.5 3.2 episodes. The age average was of 44.1 23.7 years, 56.6% women (13.5% paediatrics). The distribution of costs was a148,657,137. The total unitary cost per patient/ year 654.2 851.7a (relative weights of reference). Patient's case-mix: 57.2% of the study population was grouped into 10 ACG. The explanatory power of the ACG classification system was 36.3% (Ln: 41.2%), p 0,001. 6.2% of patients 0,001. 6.2% of patients were considered Outliers (N 14.066). It details the form skewness and the average 14.066). It details the form skewness and the average relative weights per each category of ACG's classification. CONCLUSIONS: The ACG are an acceptable system of classification of patients in situation of clinical practice use. Some ACG classification categories should be separeted due to the high categories should be separeted due to the high outliers number.
PHP40 40 THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND
Heikkonen TT 1 , Tamminen N 2 1 University of Turku, Turku, Finland, 2 Pharma Industry Finland, Helsinki, Uusimaa, Finland OBJECTIVES: To study how concentrated the Finnish pharmaceutical market is in certain medicine groups. During the last decade the Finnish authorities have implemented different acts to increase the competition in the pharmaceutical market. competition in the pharmaceutical market.
METHODS:
We examined the concentration of the pharmaceutical market by using the Herfindahl-Hirschmann Index. We calculated the index for 12 different medicine groups in 2002-2008. Ten of these groups were prescription medicines and two were ption medicines and two were self-care medicines. The index is calculated by summing up the squares of the market shares for all the firms operating in the medicine group. It is important that all medicines in each group can be substituted to each other. The index value varies between 1/n 1, n firms. Greater value of the HHI indicates greater concentration. If HHI is below 0.18 there is no concentration at all. RESULTS: In 2002 the total HHI average for the 12 groups was 0.30 as in 2008 it was 0.22. In anti-dementia drugs .22. In anti-dementia drugs the index dropped from 0.48 to 0.23. In triptans the index dropped from 0.40 to 0.17. The smallest index was seen in antiallergics. In 2002 the index in this group was 0.14 and in 2008 it was 0.12. In 2008 the most concentrated group according to the index was the protone pump inhibitors. The index in this group was 0.38. CONCLUSIONS: From 2002 to 2008 the concentration in medicine groups has clearly diminished. The difference between these groups is partly due to patents. The two self-care medicine o self-care medicine groups used in the study are clearly less concentrated than the prescription medicine groups. However, the average for all 12 groups is 0.22 and exceeds the index point of 0.18. This indicates that among the medicine groups used in calculations the market is still concentrated.
PHP41 41 LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM: ASSESSING THE ADVERSE EFFECTS
Arickx F, Soete E, VanHaeren E, Bormans V RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium OBJECTIVES: To examine if the introduction of a lump sum reimbursement system for pharmaceuticals in Belgian hospitals for hospitalized patients resulted in shifts in Health Insurance expenses (third party payer) for pharmaceuticals from an inpatient setting (hospitalized patients) to an out-patient setting (day clinic, public pharmacies, . . .), based on an analysis of financial data of NIHDI. METHODS: In july 2006, a partial (approximately 75% of the expenses) lump sum reimbursement system was introduced for standard medication (excluding new expensive drugs, oncolytics, orphan drugs, . . .) fixing budgets per hospital, per hospitalization, based on patient profiles (APRDRG, All patients Refined Diagnosis Related Groups) and financial data. Using registered financial data from NIHDI the evolution of the Health Insurance expenses for pharmaceuticals in hospitals was examined. RESULTS: The yearly expenses for pharmaceuticals for hospitalized patients grew with 8.0%, 0.2%, 2.0%, 0.1% and 1.6% in the period 2003-2008. For patients in day clinic the growth was respectively 23.7%, 11.7%, 5.8%, 19.3% and 17,9%. For patients in public pharmacies these figures were 8.2%, 1.2%, 2.3%, 6.2% and 12.2%. CONCLUSIONS: Evaluation of the data shows no changes in the trend in evolution of the expenses for any type of patients other than leveling of the growth in the period 2005-2006-similar to the evolution of expenses for pharmaceuticals in the other OECD countries-and a additional growth in expenses in public pharmacies ( 6,2%) due to the inclusion of self-employed persons in the general system for compulsory health insurance in 2008. Analysis shows no shifts in expenses from one setting to another.
PHP42 PHARMACEUTICAL EXPENDITURE AND POTENTIAL AVENUES FOR COST CONTAINMENT IN IRELAND
Heaney RM 1 , Judge G 1 , Fortescue-Webb D 1 , Coughlan JJ 1 , Barry M 2 1 Trinity College Dublin, Dublin 8, Dublin, Ireland, 2 National Centre for Pharmacoeconomics, Dublin, Ireland OBJECTIVES: In view of the 6-fold increase in drug expenditure over the past decade in Ireland, we set out to identify primary areas of utilisation and expenditure under the Community Drugs Schemes and explore strategies for cost containment. METHODS: We examined the Statistical Analysis of Claims and Payments for 2007/2008 from the Primary Care Reimbursement Service (PCRS). This is a definitive measure of general practitioner prescribing rates and enabled us to determine utilization and expenditure. We applied the autoregressive integrated moving average (ARIMA) model to the national prescribing database to predict future expenditure on medicines. RESULTS: In 2008 expenditure under the Community Drugs Schemes was a2.289 billion with over 60.5 million prescription items. The ARIMA model predicts that expenditure will continue to rise reaching a2.3-a3 billion by 2012. The 60.5 million prescription items are distributed as follows: General Medical Services Scheme (GMS) 73%, Long Term Illnesses Scheme 4% (both free to patients), Drug Payments Scheme 22%, High Technology Drugs and others account for the remaining 1%. The major therapeutic classifications by cost under the GMS are Cardiovascular System 23.9%, Nervous System 20.5%, Alimentary Tract and Metabolism 15.4%. Cost containment measures could include: increasing generic drug utilisation rates from 18.3% (2.4% unbranded, 15.9% branded; EU average 50%); decreasing wholesale margin from 15%; changing current drug schemes by introducing disinvestment measures and patient co-payments; reducing the pharmacy 50% mark-up and introducing reference pricing whilst continuing to reward innovation. CONCLUSIONS: It is clear that the current trend of increasing drug expenditure will continue and the measures we have suggested above would be efficient strategies for cost containment.
PHP43 INTERNATIONAL PAYER RESARCH: COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK
de Cambra S 1 , Mladsi D 2 , Neale S 3 1 RTI Health Solutions, Barcelona, Spain, 2 RTI Health Solutions, Research Triangle Park, NC, USA, 3 RTI-Health Solutions, Ottawa, Ontario, Canada OBJECTIVES: Global pharmaceutical companies often conduct coordinated, multicountry studies to elicit information from payers and those who influence their decisions. Such studies can influence global product value strategy and increase the likelihood of positive pricing and reimbursement (P&R) decisions. Differences in P&R systems across markets must be considered. The aim of this study was to compare payer roles in three pharmaceutical markets (UK, Spain, Canada), and to evaluate the usefulness of various qualitative research methods in eliciting information to inform a global product value strategy. METHODS: We conducted a review of publicly available guidance and qualitative payer research to develop a framework for comparing optimal approaches to qualitative payer research. We compared the levels at which pricing, reimbursement, and market access decisions are made (e.g., national, regional, local, hospital), bodies influencing payer decisions (e.g., health technology assessment agencies), and the processes of engagement among physicians, patients, and payers. Implications of various qualitative and quantitative research techniques on a pharmaceutical company's ability to devise an effective global strategy are discussed. RESULTS: Treatment location (outpatient drug, hospital only) and type of prescriber must be considered when determining the research strategy in Spain. In Canada, provincial drug plans make reimbursement decisions for outpatient drugs considering Common Drug Review recommendations. Hospital formulary committees assess drugs for hospital use. NICE, the Scottish Medicines Consortium and the All Wales Medicines Strategy Groups make decisions at the national level in the UK while Primary Care Trusts make funding decisions in the absence of NICE appraisal in England. CONCLUSIONS: For multi-country payer research to be useful for devising a global value strategy it is important to understand the pricing and reimbursement systems in different countries and to identify properly the key stakeholders.
PHP45 THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES-WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES
White J Novo Nordisk A/S, Zurich, Switzerland OBJECTIVES: Assessment of health technology (HTA), including pharmaceuticals, devices, procedures and organizational systems plays an increasingly important role in health care systems by providing structured, evidence-based input to policymaking. HTA is firmly established in Europe, North America and Australasia, and is growing rapidly in Asia and Latin America. We investigated the organisation and influence of HTA in middle-income countries on real decision-making over pharamceutical budgets. METHODS: We selected middle-income countries where HTA activities are establihsed to some extent: Argentina, Brazil, China, Colombia, Israel, Mexico, Philippines, Korea, Taiwan, Thailand, and Turkey. We collected and reviewed relevant information to describe the health care and reimbursement systems and how HTA relates to coverage decision making of pharmaceuticals using a common template. The country profiles were supplemented by information from a structured web-survey among professionals working in public and private health insurance, industry, regulatory authorities, ministries of health, academic units or HTA agencies. RESULTS: The use and implementation of HTA recommendations in reimbursement decision-making is still in its early stages. We found that in South Korea, Taiwan, Brasil and Mexico HTA was more developed, with guidelines for manufacturers submissions, a link to the pricing of new treatments and some requirement for data to be adapted for local costs epidemiology. CONCLUSIONS: The study provides evidence of the development of HTA in coverage decision making in middle-income countries. Increased health care spending and the resulting access to modern technology give a strong impetus to HTA. The assessment and regulation of pharmaceuticals are advanced in relation to other technologies. HTA is developing with uneven speed in middle-income countries; many countries are building on the organisational and methodological experience from established HTA agencies in Europe, Australia and Canada.
PHP46 WTP FOR A QALY: THE INDIVIDUAL PERSPECTIVE
Bobinac A Erasmus University, Rotterdam, The Netherlands OBJECTIVES: Elicit the individual willingness to pay (WTP) for a QALY. METHODS: Web-based contingent analysis included 1091 respondents, representative of the Dutch population. Individuals solved 5 scenarios with two health states each. They initially valued health states on VAS scale, then indicated which health state was worse and finally expressed their WTP for avoiding a given decline in health. WTP was elicited in an open-ended format and from a payment scale. Respondents had to indicate the degree of certainty in the answers provided. WTP/QALY was calculated one for every utility elicitation technique, WTP elicitation technique (payment scale and open-ended questions) and each scenario. The heterogeneity in WTP/QALY ratios was examined from the perspective of 1) household income, and 2) the level of certainty in WTP
